Daeiou Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 14.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 11.71 Cr
as on 24-10-2024
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.25 Cr
as on 24-10-2024
- Revenue 2.59%
(FY 2023)
- Profit -7804.73%
(FY 2023)
- Ebitda -5284.02%
(FY 2023)
- Net Worth 47.50%
(FY 2023)
- Total Assets 42.96%
(FY 2023)
About Daeiou Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 14.00 Cr and a paid-up capital of Rs 11.71 Cr.
The company currently has active open charges totaling ₹7.25 Cr.
Raghuraman Parthasarathy, Elamurugaraja Muthusamy, Aruljothi Srinivasan, and Seven other members serve as directors at the Company.
- CIN/LLPIN
U24232PY2009PTC002373
- Company No.
002373
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Oct 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pondicherry
Industry
Company Details
- Location
Villupuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Daeiou Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Murugesan Jayakumar | Managing Director | 19-Mar-2023 | Current |
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghuraman Parthasarathy  | Director | 23-Feb-2019 | Current |
| Elamurugaraja Muthusamy | Director | 20-Apr-2019 | Current |
| Aruljothi Srinivasan | Director | 20-Apr-2019 | Current |
| Vivekanandan Sumathi | Director | 19-Mar-2023 | Current |
| Nalliyappan Shanmugapriya | Director | Current | |
| Ramasamy Kanagaraj | Additional Director | 19-Mar-2023 | Current |
Financial Performance of Daeiou Pharmaceuticals.
Daeiou Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.59% increase. The company also saw a substantial fall in profitability, with a 7804.73% decrease in profit. The company's net worth Soared by an impressive increase of 47.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Daeiou Pharmaceuticals?
In 2023, Daeiou Pharmaceuticals had a promoter holding of 27.74% and a public holding of 72.26%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rhythm Formulations Private LimitedActive 15 years 7 monthsRaghuraman Parthasarathy is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Aug 2024 | ₹3.35 Cr | Open |
Others Creation Date: 20 Aug 2024 | ₹3.50 Cr | Open |
Indian Overseas Bank Creation Date: 21 Aug 2012 | ₹4.00 M | Open |
How Many Employees Work at Daeiou Pharmaceuticals?
Daeiou Pharmaceuticals has a workforce of 32 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Daeiou Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daeiou Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
